

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BAMBOOS HEALTH CARE HOLDINGS LIMITED

百本醫護控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2293)

PROFIT WARNING

This announcement is made by Bamboos Health Care Holdings Limited (the “**Company**” and, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the year ended 30 June 2026 (the “**Year**”) and information currently available to the Board, the Group is expected to record net profits attributable to the Shareholders in the range of approximately HK\$6 million to HK\$7 million for the Year, as compared to the audited consolidated net profits attributable to the Shareholders of approximately HK\$17.5 million for the year ended 30 June 2025.

The Board considers that the reduction in net profits attributable to the Shareholders is mainly attributable to the following factors:

- (i) The Group’s revenue dropped mainly in the institutional healthcare staffing solutions sector, declining to approximately HK\$22 million to HK\$23 million from last year’s HK\$35.1 million. This decrease was due to the policies implemented by the Hong Kong Government in response to manpower shortages, especially the introduction of the imported labor scheme which imports nurses and care workers from overseas, mainly the Mainland China. These policies boosted the labor supply for institutional healthcare clients, leading to intensified market competition.
- (ii) an increase in other losses by approximately HK\$2 million to HK\$3 million compared to last year, mainly attributable to exchange differences arising from foreign currency transactions.

- (iii) the clinic services sector was experiencing a rise in direct costs of approximately HK\$2 million to HK\$3 million, primarily driven by higher medicines and laboratory expenses compared to last year.

The Company is in the process of finalising the Group's results for the Year. The information contained in this announcement is only a preliminary assessment by the Board based on the latest unaudited management accounts of the Group and information currently available and is not based on any figures or information which has been audited or reviewed by the Company's auditors. The actual results of the Group for the Year may differ from what is disclosed in this announcement.

Shareholders and potential investors are advised to read carefully the annual results announcement for the Year, which is expected to be published in late September 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Bamboos Health Care Holdings Limited
Hai Hiu Chu
Chairman

Hong Kong, 9 September 2026

As at the date of this announcement, the executive Director is Ms. Hai Hiu Chu and the independent non-executive Directors are Dr. Chan Kai Yue Jason, Mr. Wong Kon Man Jason and Mr. Tang Yi Hoi.